A composition for promoting skin wound healing and barrier repair, its preparation method and application

Abstract

The present application discloses a composition for promoting skin wound healing and barrier repair, its preparation method and application, belonging to the technical field of traditional Chinese medicine. The composition for promoting skin wound healing and barrier repair comprises the following components: Codonopsis pilosula, Cistanche deserticola, Gastrodia elata and Astragalus membranaceus. In the present application, Codonopsis pilosula, Cistanche deserticola, Gastrodia elata and Astragalus membranaceus which are both edible and medicinal are used in combination, so that the functions of each component can be integrated and synergistic effects can be achieved. The obtained composition can safely and efficiently promote skin wound healing and barrier repair, is expected to shorten the treatment cycle, and provides an efficient and safe treatment plan for skin injuries.

Description

Technical Field

[0001] This application relates to the technical field of traditional Chinese medicine, and particularly to a composition for promoting skin wound healing and barrier repair, its preparation method and application. Background Art

[0002] The skin, as the largest organ of the human body, acts as a crucial barrier to protect the body from the external environment. When the skin is damaged, wound healing and barrier repair become the core processes for restoring its function. However, wound healing is a complex and multi-stage process, involving the coordinated actions of various cell types and molecular signals such as inflammatory responses, cell proliferation, and migration. At the same time, barrier repair depends on the proliferation and differentiation of epidermal cells (such as keratinocytes), as well as the expression and regulation of barrier proteins (such as keratin, tight junction proteins, etc.). Under normal physiological conditions, the skin has a certain self-repair ability and can effectively cope with daily injuries. However, in some pathological conditions, such as ultraviolet (UV) damage or diabetes, the skin's repair ability is significantly inhibited. This may lead to delayed wound healing and severe impairment of the skin barrier function, thereby affecting the overall health and function of the skin.

[0003] Currently, the treatment methods for skin wounds mainly include drug therapy, biological dressings, and physical therapy, etc. For drug therapy, researchers have discovered some monomer drugs that can promote wound healing, such as growth factors, cytokines, and antioxidants, etc. However, when these drugs are used alone, they often have problems such as limited effects, long treatment cycles, and potential side effects.

[0004] Therefore, finding more effective drug combinations to promote wound healing and barrier repair has become a research hotspot in the field of skin injury treatment. For example, there is a method that combines growth factors with hyaluronic acid to accelerate wound healing by promoting cell proliferation and providing a moist environment; there is a method that combines vitamin C with zinc to improve skin barrier function by antioxidant and promoting collagen synthesis; there is a method that combines rapamycin with metformin to repair chronic wounds by inhibiting inflammation and promoting autophagy. However, the above combination drugs still have quite limited effects on skin injury treatment, and all are based on chemical drugs, inevitably having potential side effects.

[0005] Based on this, it is necessary to provide a composition that can safely and efficiently promote skin wound healing and barrier repair. Summary of the Invention

[0006] Based on this, the main object of this application is to provide a composition that can safely and efficiently promote skin wound healing and barrier repair, and provide an efficient and safe treatment plan for skin injuries.

[0007] In the first aspect of the present application, a composition for promoting skin wound healing and barrier repair is provided, comprising the following components: Codonopsis pilosula, Cistanche deserticola, Gastrodia elata, and Astragalus membranaceus.

[0008] In some embodiments, by weight parts, the composition for promoting skin wound healing and barrier repair comprises: 40 - 60 parts of Codonopsis pilosula, 400 - 600 parts of Cistanche deserticola, 40 - 60 parts of Gastrodia elata, and 40 - 60 parts of Astragalus membranaceus.

[0009] In some embodiments, by weight parts, the composition for promoting skin wound healing and barrier repair comprises: 50 parts of Codonopsis pilosula, 500 parts of Cistanche deserticola, 50 parts of Gastrodia elata, and 50 parts of Astragalus membranaceus.

[0010] In the second aspect of the present application, a preparation method of a composition for promoting skin wound healing and barrier repair is provided, comprising the following steps:

[0011] Take each component and mix them to prepare the composition for promoting skin wound healing and barrier repair.

[0012] In the third aspect of the present application, an application of the composition for promoting skin wound healing and barrier repair described in the first aspect in the preparation of a product for promoting skin wound healing and barrier repair is provided.

[0013] In the fourth aspect of the present application, a product for promoting skin wound healing and barrier repair is provided, comprising the composition for promoting skin wound healing and barrier repair described in the first aspect.

[0014] In some embodiments, the product comprises a drug.

[0015] In some embodiments, the dosage form of the drug comprises a solid dosage form, a semi - solid dosage form, or a liquid dosage form.

[0016] In some embodiments, the drug comprises excipients.

[0017] In some embodiments, the usage mode of the drug comprises oral administration or external application.

[0018] Advantages of the present application:

[0019] 1. The present application uses the compound use of Codonopsis pilosula, Cistanche deserticola, Gastrodia elata, and Astragalus membranaceus which are both edible and medicinal, can integrate the functions of each component, and synergistically enhance the effect. The obtained composition can safely and efficiently promote skin wound healing and barrier repair, is expected to shorten the treatment cycle, and provides an efficient and safe treatment plan for skin injuries.

[0020] 2. The components of the composition for promoting skin wound healing and barrier repair in the present application are all Chinese medicinal materials that are both edible and medicinal, with easily available raw materials and are safe and harmless. Description of the Drawings

[0021] To more clearly illustrate the technical solutions in the embodiments of the present application or the prior art, the following will briefly introduce the accompanying drawings required for the description of the embodiments or the prior art. The accompanying drawings are only for the purpose of showing the preferred embodiments and are not considered to limit the present application. Throughout the accompanying drawings, the same reference numerals are used to represent the same components. In the accompanying drawings:

[0022] Figure 1 is the scratch area at 0 hours and 48 hours for different groups;

[0023] Figure 2 is the healing rate of HaCaT cells after 48 hours for different groups;

[0024] Figure 3 is the effect of the composition for promoting skin wound healing and barrier repair in Example 1 on the expression of barrier-related proteins. Detailed Embodiments

[0025] To make the objectives, technical solutions and advantages of the present application clearer and the understanding of the disclosed content of the present application more thorough and comprehensive, the following will clearly and completely describe the technical solutions of the present application in combination with the specific embodiments and the corresponding accompanying drawings of the present application. The described embodiments are only a part of the embodiments of the present application, rather than all of the embodiments.

[0026] The following will make a detailed description of the implementation of the present application in combination with the accompanying drawings. This embodiment is implemented on the premise of the technical solution of the present application, and gives detailed implementation manners and specific operation processes, but the protection scope of the present application is not limited to the following embodiments.

[0027] Unless otherwise defined, all technical and scientific terms used in the present application have the same meanings as those commonly understood by those skilled in the technical field to which the present application belongs. The terms used in the specification of the present application are only for the purpose of describing specific embodiments and are not intended to limit the present application.

[0028] Term

[0029] Unless otherwise stated or there are contradictions, the terms or phrases used in the present application have the following meanings:

[0030] In the present application, when it comes to "a plurality of", "a variety of", etc., unless otherwise specified, it means greater than 2 or equal to 2 in quantity. For example, "one or more", "at least one" means one or greater than or equal to two.

[0031] In the present application, "further", "especially", etc. are used to describe the purpose and indicate differences in content, but should not be understood as limiting the protection scope of the present application.

[0032] In this application, among the technical features described in an open-ended manner, it includes a closed technical solution composed of the listed features, and also includes an open technical solution containing the listed features.

[0033] In this application, when it comes to a numerical interval (i.e., a numerical range), unless otherwise specified, the distribution of the selectable numerical values within this numerical interval is considered continuous, and it includes the two numerical endpoints of this numerical interval (i.e., the minimum value and the maximum value), as well as each numerical value between these two numerical endpoints. Unless otherwise specified, when the numerical interval only refers to the integers within this numerical interval, it includes the two endpoint integers of this numerical range, as well as each integer between the two endpoints, which is equivalent to directly listing each integer. When providing multiple numerical ranges to describe features or characteristics, these numerical ranges can be combined. In other words, unless otherwise specified, the numerical ranges disclosed in this application should be understood to include any and all sub-ranges subsumed therein. The "numerical value" in this numerical interval can be any quantitative value, such as a number, a percentage, a ratio, etc. The "numerical interval" allows for a broad inclusion of numerical interval types such as a percentage interval, a ratio interval, a ratio value interval, etc.

[0034] In this application, unless otherwise specified, the temperature parameter allows for both constant temperature treatment and variation within a certain temperature interval. It should be understood that the so-called constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. Fluctuations within ranges such as ±5°C, ±4°C, ±3°C, ±2°C, and ±1°C are allowed.

[0035] The term "and / or" used in this application includes any and all combinations of one or more of the related listed items.

[0036] In this application, for the temperature parameter, unless otherwise specified, it allows for both constant temperature treatment and treatment within a certain temperature interval. The so-called constant temperature treatment allows the temperature to fluctuate within the accuracy range controlled by the instrument. The room temperature referred to in this application means 0°C - 40°C, preferably 10°C - 35°C, and more preferably 20°C - 30°C.

[0037] In the first aspect of this application, there is provided a composition for promoting skin wound healing and barrier repair, which includes the following components: Codonopsis pilosula, Cistanche deserticola, Gastrodia elata, and Astragalus membranaceus.

[0038] Codonopsis pilosula is a plant of the genus Codonopsis in the family Campanulaceae. It is a traditional Chinese medicine for replenishing qi that is widely used in clinical practice of traditional Chinese medicine. Its chemical components mainly include flavonoids, alkaloids, saccharides, saponins, steroids, amino acids, etc. It can promote the regeneration and repair of skin cells, help improve the skin texture, and make the skin smoother and more delicate. In addition, the active ingredients of Codonopsis pilosula can also protect melanocytes from oxidative stress damage by activating the autophagy mechanism, thereby maintaining the skin homeostasis.

[0039] Active components in Astragalus membranaceus, such as Astragalus polysaccharides and saponins, can promote the proliferation and differentiation of skin cells and accelerate the repair of skin tissue. For example, in the treatment of burns and scalds, Astragalus membranaceus can significantly shorten the healing time and reduce scar formation. Its flavonoid compounds can inhibit the generation and release of inflammatory mediators, reduce skin inflammatory responses, and have antioxidant capacity, which can scavenge free radicals, reduce the damage of oxidative stress to the skin, and delay skin aging.

[0040] Gastrodia elata, as a substance with both medicinal and edible uses, is a perennial herb of the genus Gastrodia in the Orchidaceae family. Gastrodia elata contains various antioxidant components, such as flavonoid compounds and triterpenoid compounds, which can resist the invasion of free radicals, protect the skin from oxidative damage, and thus delay skin aging. In addition, the polysaccharide component in Gastrodia elata can increase skin elasticity and inhibit skin aging.

[0041] The polysaccharide component in Cistanche deserticola can promote the regeneration and repair of skin cells, help damaged skin recover to health; and has significant moisturizing ability, which can increase the water content of the skin and maintain the normal function of the skin barrier. In addition, Cistanche deserticola is rich in various antioxidant components, such as phenyl ethanol glycosides, polysaccharides, etc., which can effectively scavenge free radicals, reduce the damage of oxidative stress to the skin, and delay skin aging. These components can reduce skin aging symptoms such as wrinkles and age spots, and at the same time enhance the elasticity and luster of the skin.

[0042] In this application, the wound healing effect and the expression of skin barrier proteins (key indicators for evaluating the recovery of skin barrier function) are used as evaluation indicators. Combining with pharmacological characteristics, a large number of experiments have been carried out on the combined effects of ingredients with both medicinal and edible uses. Finally, a combination scheme of Codonopsis pilosula, Cistanche deserticola, Gastrodia elata and Astragalus membranaceus has been preferably obtained.

[0043] It has been found through research that the combined use of Codonopsis pilosula, Cistanche deserticola, Gastrodia elata and Astragalus membranaceus with both medicinal and edible uses can integrate the functions of each component and synergistically enhance the effect. The obtained composition can effectively promote skin wound healing and barrier repair, is expected to shorten the treatment cycle, and provides an efficient and safe treatment plan for skin damage.

[0044] In a specific example, by weight, the composition for promoting skin wound healing and barrier repair includes: 40 - 60 parts of Codonopsis pilosula, 400 - 600 parts of Cistanche deserticola, 40 - 60 parts of Gastrodia elata, and 40 - 60 parts of Astragalus membranaceus.

[0045] In a specific example, by weight, the composition for promoting skin wound healing and barrier repair includes: 50 parts of Codonopsis pilosula, 500 parts of Cistanche deserticola, 50 parts of Gastrodia elata, and 50 parts of Astragalus membranaceus.

[0046] In the second aspect of this application, a preparation method of a composition for promoting skin wound healing and barrier repair is provided, including the following steps:

[0047] Mix each component to prepare the composition for promoting skin wound healing and barrier repair.

[0048] In a specific example, a powder-making step is further included before or after mixing.

[0049] In the third aspect of the present application, there is provided an application of the composition for promoting skin wound healing and barrier repair described in the first aspect in the preparation of a product for promoting skin wound healing and barrier repair.

[0050] In a specific example, the promotion of skin wound healing includes promoting the migration and healing of human skin keratinocytes.

[0051] In a specific example, the promotion of skin barrier repair includes increasing the expression of skin barrier proteins after UV light damage.

[0052] In the fourth aspect of the present application, there is provided a product for promoting skin wound healing and barrier repair, including the composition for promoting skin wound healing and barrier repair described in the first aspect.

[0053] In a specific example, the product includes a drug.

[0054] In a specific example, the dosage form of the drug includes a solid dosage form, a semi-solid dosage form or a liquid dosage form.

[0055] In a specific example, the drug includes excipients.

[0056] It is understandable that the solid dosage form includes powder, tablet, capsule, pill or granule; the semi-solid dosage form includes ointment, gel plaster or patch; the liquid dosage form includes solution, syrup, emulsion or tincture.

[0057] In addition to the active compound, the liquid dosage form may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers. Specifically, for example, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide and oils. In addition to these inert diluents, the composition may also contain auxiliaries, such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and fragrances. For example, the suspension may contain a suspending agent, specifically, ethoxylated isooctadecanol, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum methoxide and agar or a combination thereof.

[0058] In addition to the active compound, the semi-solid dosage form may include conventional matrices and excipients. Depending on the specific dosage form, the corresponding matrix or excipient can be selected. For example, common matrices for ointments include petrolatum, lard, lanolin, etc.; common matrices and excipients for pastes include glycerin, liquid paraffin, etc.; other active ingredients can be appropriately added to extracts; common matrices for licks include starch, syrup, vegetable oil, etc.

[0059] In addition to the active compound, the solid dosage form may contain conventional inert excipients, such as: (a) fillers or bulking agents, such as starch, lactose, sucrose, glucose, mannitol, and silicic acid; (b) binders, such as hydroxypropylmethylcellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (e) solubilizing agents, such as paraffin wax; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium lauryl sulfate, or a mixture thereof. In capsules, tablets, and pills, the dosage form may also contain buffering agents. Solid dosage forms such as tablets, dragees, capsules, pills, or granules can be prepared with coatings and shell materials, such as enteric coatings and other materials well-known in the art. They may contain opacifying agents, and the release of the active compound or compounds in such a composition can be delayed and released in a certain part of the digestive tract. Examples of embedding components that can be used are polymeric substances and wax-like substances. If necessary, the active compound can also be in the form of microcapsules with one or more of the above excipients.

[0060] In a specific example, the excipients include one or more of solvents, solubilizers, emulsifiers, fragrances, wetting agents, flavoring agents, clarifying agents, fillers, diluents, binders, and preservatives.

[0061] In a specific example, the drug can be used orally or topically.

[0062] In a specific example, the working concentration of the drug is 100 μg / mL - 2000 μg / mL, such as 100 μg / mL, 200 μg / mL, 300 μg / mL, 400 μg / mL, 500 μg / mL, 600 μg / mL, 700 μg / mL, 800 μg / mL, 900 μg / mL, 1000 μg / mL, 1200 μg / mL, 1400 μg / mL, 1600 μg / mL, 1800 μg / mL, 2000 μg / mL.

[0063] Unless otherwise specified, the raw materials used in the following tests can be routinely purchased on the market. The following is an exemplary description of the raw materials in the examples and comparative examples.

[0064] Dangshen powder: purchased from Guangdong Qingyunshan Pharmaceutical Co., Ltd.

[0065] Astragalus membranaceus powder: purchased from Guangdong Qingyunshan Pharmaceutical Co., Ltd.

[0066] Gastrodia elata powder: purchased from Guangdong Qingyunshan Pharmaceutical Co., Ltd.

[0067] Cistanche deserticola powder: purchased from Guangdong Qingyunshan Pharmaceutical Co., Ltd.

[0068] Schisandra chinensis powder, Crocus sativus powder, Salvia miltiorrhiza powder: purchased from Shen'ao Chinese Medicinal Materials.

[0069] The following are specific examples. Example 1

[0070] Mix 50 parts of Dangshen powder, 500 parts of Cistanche deserticola powder, 50 parts of Gastrodia elata powder and 50 parts of Astragalus membranaceus powder to prepare a composition for promoting skin wound healing and barrier repair. Example 2

[0071] Mix 40 parts of Dangshen powder, 600 parts of Cistanche deserticola powder, 40 parts of Gastrodia elata powder and 40 parts of Astragalus membranaceus powder to prepare a composition for promoting skin wound healing and barrier repair. Example 3

[0072] Mix 60 parts of Dangshen powder, 400 parts of Cistanche deserticola powder, 60 parts of Gastrodia elata powder and 60 parts of Astragalus membranaceus powder to prepare a composition for promoting skin wound healing and barrier repair.

[0073] Comparative Example 1

[0074] Except that the Gastrodia elata powder is replaced with Cistanche deserticola powder, the rest is the same as Example 1.

[0075] Comparative Example 2

[0076] Except that the Cistanche deserticola powder is replaced with Gastrodia elata powder, the rest is the same as Example 1.

[0077] Comparative Example 3

[0078] Except that the Cistanche deserticola powder is replaced with Salvia miltiorrhiza powder, the rest is the same as Example 1.

[0079] Comparative Example 4

[0080] Except that the Cistanche deserticola powder is replaced with Schisandra chinensis powder, the rest is the same as Example 1.

[0081] Comparative Example 5

[0082] Except that the Cistanche deserticola powder is replaced with Crocus sativus powder, the rest is the same as Example 1.

[0083] Comparative Example 6

[0084] Except that the cistanche powder was replaced with astragalus powder, the rest was the same as in Example 1.

[0085] The formulations of Examples 1-3 and Comparative Examples 1-6 are shown in Table 1.

[0086] Table 1 Formulations of Examples 1-3 and Comparative Examples 1-6

[0087]

[0088] Test Example 1: Effect of the composition for promoting skin wound healing and barrier repair on the cell migration of human immortalized keratinocytes (HaCaT)

[0089] The specific test steps are as follows:

[0090] 1. Cell seeding and scratching: Using human immortalized keratinocytes (HaCaT) as the test object, in an incubator environment of 5% CO2 and 37 °C, HaCaT cells were cultured using DMEM medium containing 10% fetal bovine serum. When the cells were in the logarithmic growth phase, they were digested with 0.25% trypsin to obtain a cell suspension. Take the cell suspension and transfer it to a 6-well culture plate at 7×10 5 cells / well. Incubate for another 24 hours. After the cells grew to confluence, use a 200 μL pipette tip to scratch the well plate. Wash the cells 3 times with PBS to remove the scratched cells.

[0091] 2. Cell drug administration and photography: Dilute the drug with 1% low-serum medium. The total concentration of the compositions of Examples 1-3 and Comparative Examples 1-6 was 650 μg / mL (the control group was added with an equal amount of 1% low-serum medium). After continuing to incubate in the incubator for 48 hours, take pictures to record the scratch area at the initial 0 hour and 48 hours, see Figure 1 .

[0092] 3. Result calculation: Use Image J to measure the scratch area and perform statistics according to the following formula: Scratch healing rate (%) = [1 - (scratch area at 48 hours / scratch area at 0 hour)] × 100%. The results are shown in Figure 2 .

[0093] From Figure 2It can be seen that after the intervention of the compositions with different concentrations for promoting skin wound healing and barrier repair, the cell scratch healing rate of Example 1 is 86.76%, the cell scratch healing rate of Example 2 is 80.59%, and the cell scratch healing rate of Example 3 is 74.39%, which is higher than the healing rate of the control group (58.85%). It can be seen that the compositions for promoting skin wound healing and barrier repair in Examples 1-3 have a significant ability to promote cell healing, and Example 1 has the best effect.

[0094] By comparing Example 1 with Comparative Examples 1-2, it can be seen that on the basis of using codonopsis powder and astragalus powder, Example 1 uses cistanche powder and gastrodia powder in combination, which can significantly increase the scratch healing rate (from 41.71%-66.27% to 86.76%) compared with Comparative Examples 1-2 that only use the same amount of cistanche powder or gastrodia powder. It can be seen that the combined use of cistanche powder and gastrodia powder can have a synergistic effect.

[0095] By comparing Example 1 with Comparative Examples 3-5, it can be seen that on the basis of using codonopsis powder, astragalus powder and gastrodia powder, using cistanche powder can significantly increase the scratch healing rate compared with schizandra powder, saffron powder and salvia powder. Among them, when using schizandra powder, saffron powder and salvia powder, the scratch healing rate is significantly lower than that of the control group. It can be seen that the use of the above three medicinal materials not only cannot promote scratch healing, but also has an adverse effect on wound healing.

[0096] By comparing Example 1 with Comparative Example 6, it can be seen that on the basis of using codonopsis powder and gastrodia powder, Example 1 uses cistanche powder and astragalus powder in combination, which significantly increases the scratch healing rate (an increase of 39.59%) compared with Comparative Example 6 that only uses the same amount of astragalus powder. It can be seen that the combined use of cistanche powder and astragalus powder has a significantly better effect than using astragalus powder alone.

[0097] Test Example 2: Effect of the composition for promoting skin wound healing and barrier repair on the expression of skin barrier proteins in a UV-stimulated mouse skin keratinocyte (HaCaT) injury model

[0098] 1. Cell seeding: When HaCaT cells grow to an appropriate passage number, after digestion and counting, they are seeded in a 10 cm cell culture dish at a density of 2×10 6 / mL and placed in a cell culture incubator at 37 °C, 5% CO2 and saturated humidity.

[0099] 2. Cell administration: Control group (without modeling), model group (irradiated with UVA for 120 minutes), and Example 1 group (after UVA irradiation for 120 minutes, the composition for promoting skin wound healing and barrier repair of Example 1 was administered). When the cells in the 10-cm dish grew to 80% confluence, 10 mL of DMEM complete medium containing 650 μg / mL of the composition for promoting skin wound healing and barrier repair was added to the Example 1 group, and 10 mL of DMEM complete medium was added to each well of the control group and the model group. Three replicate wells were set in each group. After drug administration, the 10-cm dish was placed in a constant temperature incubator at 37 °C, 5% CO2, and saturated humidity for 24 h.

[0100] 3. Protein extraction and denaturation: The medium was removed, and the cells were washed twice with pre-cooled PBS solution. The cells were gently scraped with a cell scraper and transferred into a 15-mL centrifuge tube. After centrifugation (3000 rpm / min, 5 min), the supernatant was discarded. The cells were resuspended with 300 μL of cell lysate containing PMSF and transferred to a 1.5-mL centrifuge tube. The cells were lysed on ice for 20 min, and after centrifugation (14,000 r / min, 10 min), the supernatant was aspirated into a new 1.5-mL centrifuge tube. The total protein content was determined using a BCA kit (purchased from Beyotime). After mixing the qualified protein sample with 5x Loading Buffer, it was placed in a 100 °C metal bath for 5 min to denature the protein, and stored at -20 °C for later use.

[0101] 4. Western blot assay: Proteins with different molecular weights (primary antibodies: occludin, claudin-1, and filaggrin) were separated by precast gels with different concentrations (8% - 15%) (purchased from Sangon Biotech). The expression level of the internal reference protein (anti-mouse GAPDH) was used as the internal reference. After adding the protein sample, SDS-PAGE electrophoresis was performed at a constant voltage of 80 V for 90 min; after the PVDF membrane was activated with methanol solution for about 2 min, transfer was carried out at a constant current of 200 mA for 70 - 90 min; the PVDF membrane was blocked with 5% BSA blocking solution at room temperature for 90 min. After blocking, it was washed 3 times with 1x TBST buffer (purchased from Solarbio), 5 min each time; incubated overnight at 4 °C, and then washed with TBST solution for 10 min, 3 times the next day. After washing, the membrane was incubated in the secondary antibody at room temperature for 70 min. After completion, it was washed 3 times with TBST, 10 min each time. Positive bands were detected by the ECL method. The gray value of the positive band was analyzed using Image J software and the relative protein expression level was calculated.

[0102] Among them, the specific information of the primary antibodies is as follows:

[0103] Occludin (Anti-rabbit Occludin): Purchased from Proteintech Group, dilution ratio 1:10000, size 59 kDa;

[0104] Claudin 1 (Anti-rabbit Claudin 1): Purchased from Proteintech Group, dilution ratio 1:3000, size 20 - 23 kDa;

[0105] Filaggrin (Anti-rabbit Flg): Purchased from Affinity Biosciences, dilution ratio 1:1000, size 30 - 120 kDa;

[0106] Housekeeping protein (Anti-mouse GAPDH): Purchased from Wuhan Sanying Biotechnology Co., Ltd., dilution ratio 1:10000, size 36 kDa.

[0107] The specific information of the secondary antibody is as follows:

[0108] Anti-rabbit and anti-mouse conjugated IgG secondary antibody: Purchased from BOSTER, dilution ratio 1:80000.

[0109] After each protein was repeated 3 times, they were represented as Protein type - 1, Protein type - 2, and Protein type - 3 respectively, and the results were as Figure 3 shown. Compared with the control group, the expression levels of the barrier proteins Claudin 1, Occludin, and Filaggrin in the model group cells were significantly decreased (One-way ANOVA statistical analysis, ***p < 0.001), indicating that the UV-stimulated HaCaT cell injury model was successfully established. The composition for promoting skin wound healing and barrier repair in Example 1 was used to repair the injury, and the results showed that compared with the model group, the expression levels of the barrier proteins Claudin 1, Occludin, and Filaggrin in the Example 1 group were extremely significantly increased (One-way ANOVA statistical analysis, *p < 0.05). The above results indicate that the composition for promoting skin wound healing and barrier repair in Example 1 can promote the expression of skin barrier proteins after UV injury.

[0110] In summary, the composition for promoting skin wound healing and barrier repair in the present application can improve skin repair ability by promoting the migration and healing of human skin keratinocytes and increasing the expression of skin barrier proteins after UV light injury.

[0111] The technical features of the above-described embodiments can be combined arbitrarily. For the sake of brevity of description, not all possible combinations of the technical features in the above embodiments are described. However, as long as there is no contradiction in the combination of these technical features, it should be considered as the scope recorded in this specification.

[0112] The above-described embodiments merely represent several implementation manners of the present application. The description thereof is relatively specific and detailed, but it should not be construed as a limitation on the scope of the invention patent. It should be noted that for those of ordinary skill in the art, without departing from the concept of the present application, several modifications and improvements can still be made, and these all fall within the protection scope of the present application. Therefore, the protection scope of the patent of the present application shall be subject to the appended claims.

Claims

1. A composition for promoting skin wound healing and barrier repair, characterized in that, By weight parts, the composition for promoting skin wound healing and barrier repair consists of the following components: 40 - 60 parts of Codonopsis pilosula powder, 400 - 600 parts of Cistanche deserticola powder, 40 - 60 parts of Gastrodia elata powder, and 40 - 60 parts of Astragalus membranaceus powder; The preparation method of the composition for promoting skin wound healing and barrier repair is as follows: Take each component and mix them to prepare the composition for promoting skin wound healing and barrier repair.

2. The composition for promoting skin wound healing and barrier repair according to claim 1, wherein By weight parts, the composition for promoting skin wound healing and barrier repair consists of the following components: 50 parts of Codonopsis pilosula powder, 500 parts of Cistanche deserticola powder, 50 parts of Gastrodia elata powder, and 50 parts of Astragalus membranaceus powder.

3. Use of the composition for promoting skin wound healing and barrier repair according to claim 1 or 2 in the preparation of a product for promoting skin wound healing and barrier repair.

4. A product for promoting skin wound healing and barrier repair, characterized in that, Comprising the composition for promoting skin wound healing and barrier repair according to claim 1 or 2.

5. The product according to claim 4, wherein, The product includes a drug.

6. The product according to claim 5, characterized in that The dosage form of the drug includes a solid dosage form, a semi - solid dosage form, or a liquid dosage form.

7. The product according to claim 5 or 6, characterized in that, The drug includes excipients.

8. The product according to claim 5 or 6, characterized in that, The usage mode of the drug includes oral administration or external application.

Images